Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: Prosigna PAM-50 assay
Sponsor: Dana-Farber Cancer Institute
Collaborators: NanoString Technologies, Inc.